192 patents
Utility
Phenolic Acid Lipid Based Cationic Lipids
18 May 23
Shrirang KARVE, Frank DEROSA, Apiwat WANGWEERAWONG, Saswata KARMAKAR
Filed: 31 Mar 21
Utility
Composition and Methods for Treatment of Methylmalonic Acidemia
11 May 23
The present invention provides, among other things, methods and compositions for treating methylmalonic academia (MMA) based on mRNA therapy.
Lianne Boeglin, Christian Cobaugh, Frank DeRosa, Michael Heartlein, Kim Askew
Filed: 13 Sep 19
Utility
Tricine and Citric Acid Lipids
23 Mar 23
Shrirang Karve, Frank DeRosa
Filed: 19 Jun 20
Utility
2,5-DIOXOPIPERAZINE Lipids with Intercalated Ester, Thioester, Disulfide and Anhydride Moieities
9 Mar 23
Yi Zhang, Frank DeRosa, Shrirang Karve, Michael Heartlein, Saswata Karmakar, Ryan Landis
Filed: 7 Nov 19
Utility
Formulations for Delivery of Oligonucleotides to Lung Cells
2 Mar 23
The present disclosure provides a method of pulmonarily administering an oligonucleotide to lung cells.
Balkrishen Bhat, Brian Bettencourt, Saswata Karmakar, Caroline Woo, John Androsavich, Shrirang Karve
Filed: 6 Jan 21
Utility
Methods for Purification of Messenger Rna
2 Mar 23
The present invention provides, among other things, methods for purifying high quality messenger RNA (mRNA) suitable for clinical use, without using any caustic or flammable solvents.
Jonathan Abysalh, Frank DeRosa, Cameron M. Smith, Jorel E. Vargas
Filed: 22 Jul 22
Utility
Subcutaneous Delivery of Messenger Rna
2 Mar 23
The present invention provides, among other things, methods of formulating nucleic acid-containing nanoparticles with an enzyme to afford efficient delivery of payload to a cell or tissue of interest via subcutaneous administration.
Shrirang Karve, Frank DeRosa, Zarna Bhavsar, Michael Heartlein
Filed: 15 Jun 22
Utility
Mrna Therapy for Phenylketonuria
16 Feb 23
The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset.
Frank DeRosa, Anusha Dias, Michael Heartlein
Filed: 1 Jun 22
Utility
Cationic Lipid Compounds
16 Feb 23
Frank DeRosa, Shrirang Karve, Yi Zhang
Filed: 20 Nov 19
Utility
Rectal Delivery of Messenger Rna
16 Feb 23
The present invention provides, among other things, effective methods and compositions for delivering messenger RNA (mRNA) via rectal delivery.
Shrirang Karve, Frank DeRosa, Ashish Sarode
Filed: 18 Dec 20
Utility
Composition and methods for treatment of primary ciliary dyskinesia
24 Jan 23
The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy.
Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
Filed: 7 Jan 20
Utility
Large-scale synthesis of messenger RNA
24 Jan 23
The present invention provides methods for large-scale production of a composition enriched for full-length mRNA molecules using an SP6 RNA polymerase and compositions produced using such methods and uses thereof.
Anusha Dias, Daniel Crawford, Frank DeRosa, Jonathan Abysalh, Michael Heartlein
Filed: 27 Feb 18
Utility
Cationic lipids comprising a steroidal moiety
10 Jan 23
Yi Zhang, Shrirang Karve, Frank DeRosa, Michael Heartlein
Filed: 30 May 19
Utility
Lipid nanoparticle compositions and methods for MRNA delivery
10 Jan 23
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 20 Dec 21
Utility
Dry Powder Formulations for Messenger RNA
5 Jan 23
The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
Frank DeRosa, Michael Heartlein, Shrirang Karve, Zarna Patel, Ashish Sarode
Filed: 16 May 22
Utility
Methods for Purification of Messenger RNA
29 Dec 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.
Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
Filed: 8 Jun 22
Utility
Nuclease Resistant Polynucleotides and Uses Thereof
29 Dec 22
The invention provides, among other things, methods of stabilizing mRNA and nuclease resistant mRNA prepared in accordance with such methods. hi certain embodiments, the nuclease resistant mRNA encodes a functional protein, such as enzyme, and is characterized by its resistance to nuclease digestion, increased half-life and/or its ability to produce increased amounts of the functional protein (e.g., enzyme) encoded thereby.
Michael Heartlein, Braydon Charles Guild, Frank DeRosa
Filed: 10 Jan 22
Utility
Methods for Purification of Messenger Rna
22 Dec 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution.
Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
Filed: 6 Jul 22
Utility
Methods for Purification of Messenger Rna
22 Dec 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution.
Frank DeRosa, Anusha Dias, Shrirang Karve, Michael Heartlein
Filed: 6 Jul 22
Utility
Poly(phosphoesters) for delivery of nucleic acids
20 Dec 22
Frank DeRosa, Michael Heartlein, Shrirang Karve, Yi Zhang
Filed: 11 Jun 18